The Advisory Board Company ABCO was a big mover last session, as the company saw its shares surged over 16% on the day. The upside was driven by the acquisition of a position equivalent to an 8.3% stake in Advisory Board by Elliott Associates, the activist hedge fund run by Paul Singer, which said that it believes the stock is significantly undervalued. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 30.2% in the past one-month time frame.

The company has seen eight negative revisions in the past one month, while its Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

The Advisory Board currently carries a Zacks Rank #5 (Strong Sell), while its Earnings ESP is 0.00%.

The Advisory Board Company Price

The Advisory Board Company Price | The Advisory Board Company Quote

A better-ranked stock in the same space is Cancer Genetics, Inc. CGIX, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ABCO going up? Or down? Predict to see what others think: Up or Down

The Best Place to Start Your Stock Search

Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
The Advisory Board Company (ABCO): Free Stock Analysis Report
 
Cancer Genetics, Inc. (CGIX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research